COMMUNIQUÉS West-GlobeNewswire

Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam™ Repair System and REGENETEN◊ Bioinductive Implant at AAOS 2026
02/03/2026
Uniting the most advanced technologies for biomechanical repair and biological augmentation Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase its unrivalled [...]
Filing of the 2025 Universal Registration Document
02/03/2026
Press release 2 March 2026 Information on the availability of the 2025 Universal Registration Document Paris, 2 March 2026 – Clariane (CLARI - ISIN: FR0010386334) announces the release of its 2025 Universal Registration [...]
Mise à disposition du Document d’enregistrement universel 2025
02/03/2026
Communiqué de presse Information relative à la mise à disposition du Document d’enregistrement universel 2025 Paris, le 2 mars 2026 : Clariane (CLARI - ISIN : FR0010386334) annonce la publication de son Document d’ [...]
IBA – ACQUISITION OF OWN SHARES
02/03/2026
IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, March 2 nd , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion [...]
IBA – ACQUISITION D’ACTIONS PROPRES
02/03/2026
Louvain-la-Neuve, Belgique, 2 mars 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
02/03/2026
Déclaration de transactions sur actions propres Paris, France (2 mars 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2025, EssilorLuxottica déclare que le 27 février 2026, les [...]
EssilorLuxottica: Disclosure of transactions in own shares
02/03/2026
Disclosure of transactions in own shares Paris, France (March 2, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2025, EssilorLuxottica declares that on [...]
OSE Immunotherapeutics accélère son recentrage stratégique autour de ses principaux leviers de création de valeur en phase avancée: Lusvertikimab et Tedopi®
02/03/2026
Dépriorisation de certains programmes précoces non stratégiques, conformément au plan stratégique à 3 ans 2026–2028 précédemment annoncé Aucun impact sur la visibilité financière ni sur la stratégie de financement, [...]
Pediatric Home Service Partners with Morgan’s to Expand Prescribed Pediatric Extended Care Services in Texas with New Center, Morgan’s Wonder Care
02/03/2026
SAN ANTONIO, March 02, 2026 (GLOBE NEWSWIRE) -- Pediatric Home Service (PHS), a national provider of comprehensive pediatric healthcare, is partnering with Morgan’s to bring its Prescribed Pediatric Extended Care (PPEC [...]
Valneva to Participate in Upcoming Investor Conferences
02/03/2026
Lyon (France), March 2, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming investor conferences in [...]
Valneva annonce sa participation à des conférences investisseurs
02/03/2026
Lyon (France), le 2 mars 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante feront des présentations et [...]
Award-Winning Speaker Mike Veny Launches “Coffee with Mike” Mental Health Podcast for Workplace Leaders
02/03/2026
New podcast explores employee wellness, workplace mental health, and belonging strategies for leaders and organizations NEW YORK, New York, March 02, 2026 (GLOBE NEWSWIRE) -- Lovely Refinement CEO and mental health [...]
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
02/03/2026
BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [...]
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
02/03/2026
COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annual Health Care [...]
Biomimetic Innovations Ltd Announces Upcoming Clinical Study of OsStic™ Injectable Synthetic Bone Void Filler in Tibial Plateau Fracture Fixation
02/03/2026
SHANNON, Ireland, March 02, 2026 (GLOBE NEWSWIRE) -- Biomimetic Innovations Ltd, an affiliate of PBC Biomed, an Irish medical device company specialising in biomimetic materials, today announced approval by MHRA for a [...]
Imviva Biotech Announces Acceptance of Late-Breaking Abstract Highlighting Data from Ongoing Phase 1/2 Study of CTA313 at 15th European Lupus Meeting
02/03/2026
Novel allogeneic CAR-T therapy demonstrates durable remission and immune-reset mechanism in systemic lupus erythematosus BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company [...]
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
02/03/2026
MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with [...]
Election of employee representatives to the Board of Directors of Novo Nordisk A/S
02/03/2026
Bagsværd, Denmark, 2 March 2026 – The employees in Novo Nordisk A/S have completed the election of employee representatives to the Board of Directors of Novo Nordisk A/S. The following employee representatives were [...]
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
02/03/2026
Conference Call and Webcast Scheduled for March 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage [...]

Pages